latest news releases from the newsroom
Immunomedics Announces First Patient Dosing of Veltuzumab, Resulting in a Complete Response, in Immune Thrombocytopenic Purpura
MORRIS PLAINS, N.J., Feb. 4, 2008 (PRIME NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that patient dosing has begun in a Phase I/II clinical trial evaluating the safety, tolerability and early indication of efficacy of veltuzumab, its humanized anti-CD20 monoclonal antibody, for the treatment of immune thrombocytopenic purpura (ITP).
Aventine Renewable Energy Holdings, Inc.
Aventine Schedules Conference Call for Fourth Quarter 2007 Results
PEKIN, Ill., Feb. 4, 2008 (PRIME NEWSWIRE) -- Aventine Renewable Energy Holdings, Inc. (NYSE:AVR) today announced that it plans to hold a conference call on Friday, February 22, 2008 to discuss its fourth quarter and full year 2007 results. A news release and supporting financial data will be released to the news wire services and the New York Stock Exchange after the market closes on Thursday, February 21, 2008. The conference call will take place at 8:00 a.m. central (9:00 a.m. eastern) on Friday, February 22, 2008. Information to dial in is detailed below. The full text of the news release and supporting financial data will be available the evening of Thursday, February 21, 2008 on the Company's website, http://www.aventinerei.com, in the Investor Relations section under the "Press Releases" link.